Expectations and grand valuations have led to a variety of challenges for cannabis stocks and investors of the space.
At the MJBizConINTL in Toronto last week, investors were treated to a variety of opinions on the state of the investment market for marijuana plays alongside the panel from two financial analysts.
The session — led by John Zamparo, equity research analyst with CIBC Capital Markets, and Max Mausner, senior analyst with Vantage Asset Management — examined some of the shortcomings of the stock market this year and what’s next for this sector.
When asked about the recently seen drop in value for Canadian cannabis stocks, Mausner said there’s been a real disconnect between the realistic financial goals for these companies and the results seen now.
Asked if the market is sufficiently mature at the moment, Mausner and Zamparo agree there are some mature companies but it’s too early to say for the whole investment sector. #MJBizConINTL
— Cannabis News | INN (@INN_Cannabis) September 4, 2019
After posting severe fiscal Q1 2020 losses, which cost former CEO Bruce Linton his job, Canopy Growth (NYSE:CGC,TSX:WEED) was also blamed for significant losses for its investment partner Constellation Brands (NYSE:STZ).
On the topic of the Constellation investment into Canopy Growth, Mausner said “the deal hasn’t really worked out that well.”
“I think there’s been a realization over the last three months, frankly, as we’ve seen some of the larger players miss the numbers that valuations need to come down to better reflect the fact that one forward estimates are probably still aggressive and two that there’s a higher degree of risk in hitting those numbers,” Mausner told the audience.
Zamparo added investors are realizing the market is not exactly what they had anticipated, with some challenges in terms of regulations in Canada, management turnover and weaker results.
“The public (market valuations are) nuts,” Codie Sanchez, managing director and partner with private investment firm Cresco Capital Partners, told the Investing News Network (INN). “Why would I invest in somebody that’s trading at a valuation or multiple that is almost impossible for them to hit?”
Zamparo adds he still sees a lot of investors follow an ethos from popular talk in 2016 and before, meaning metrics tied to production capacities and sizes for public cannabis companies. #MJBizConINTL
— Cannabis News | INN (@INN_Cannabis) September 4, 2019
When it comes to the US market and potential catalysts, the experts agreed investors are monitoring the potential passing of critical bills that would help the market today. Zamparo said he still expects to see some form of legalization or opening of the market in the next two years.
US-based cannabis companies with expanding operations in the fractured state markets currently see a discount compared to the Canadian players, which Zamparo said could be closed with listings for these US companies in senior exchanges.
During a talk on the growth seen for his exchange, Richard Carleton, CEO of the Canadian Securities Exchange (CSE), said so far in 2019 the listing house has seen just under US$1.2 billion in investments for US-based cannabis firms.
The executive added this number is behind when compared to the same time period from last year for the CSE.
Narbe Alexandrian, CEO of Canopy Rivers (TSX:RIV,OTC Pink:CNPOF), told INN the focus on profitability for cannabis companies from investors is a bit misguided due to the early stage of the entire sector.
Since the Constellation investment, fellow corporations like Molson Coors Brewing Company (NYSE:TAP,TSX:TAP), Anheuser-Busch InBev (NYSE:BUD) and Moosehead Breweries have all formed partnerships with cannabis producers. These, however, do not involve a massive financial investment with ownership options.
Jason Vegotsky, president and chief revenue officer of KushCo Holdings (OTCQX:KSHB), said that, in his view, no cannabis company currently operating is truly mature. Vegotsky later on told INN that the stock market is correcting as lofty expectations get adjusted in the minds of investors.
Don’t forget to look for the rest of our coverage of MJBizConINTL, with exclusive interviews and more insights from the show. You can also follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.